Novo Nordisk has entered a multi-year collaboration worth up to $550 million with RNA therapeutics startup Replicate Bioscience. The agreement centers on developing next-generation obesity and cardiometabolic disorder treatments utilizing Replicate's self-replicating RNA platform, which amplifies therapeutic protein expression duration. This deal represents Novo's efforts to diversify its pipeline beyond GLP-1 receptor agonists amid CEO transition and market pressures, reinforcing its commitment to RNA-based modalities for metabolic disease management.